Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
ESMO 2016 conference highlights

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.10.16
Views: 5782

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

ecancer blogger Dr Gyawali gives his scientific highlights from ESMO 2016, covering the likely impact of the research.

For more on niraparib in platinum-resistant ovarian cancer, ecancer spoke with Dr Mansoor Raza Mirza here.

For more on adjuvant ipilumumab for melanoma, ecancer spoke with Dr Alexander Eggermont here.

For more on ribociclib for breast cancer, ecancer spoke with Dr Gabriel Hortobagyi here.

For more on KEYNOTE-024 trial of pembrolizumab for NSCLC, ecancer spoke with Dr Martin Reck here.

For more on nivolumab for head and neck, you can read more through ecancer news.

For more on adjuvant sunitinib ecancer spoke with Dr Alian Ravaud here.

For more from Dr Gyawali, read his regular blog with ecancer here.

ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation